BR112022025675A2 - Método para determinar antígeno livre - Google Patents
Método para determinar antígeno livreInfo
- Publication number
- BR112022025675A2 BR112022025675A2 BR112022025675A BR112022025675A BR112022025675A2 BR 112022025675 A2 BR112022025675 A2 BR 112022025675A2 BR 112022025675 A BR112022025675 A BR 112022025675A BR 112022025675 A BR112022025675 A BR 112022025675A BR 112022025675 A2 BR112022025675 A2 BR 112022025675A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- antigen
- tracer
- epitope
- capture
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 8
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 239000000700 radioactive tracer Substances 0.000 abstract 6
- 239000007790 solid phase Substances 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 239000013026 undiluted sample Substances 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
Abstract
MÉTODO PARA DETERMINAR ANTÍGENO LIVRE. A presente invenção trata de um método para determinar o antígeno livre de um anticorpo em uma amostra de soro não diluído que compreende as etapas de (a) aplicar a amostra não diluída a uma fase sólida na qual um anticorpo de captura foi imobilizado para formar um complexo anticorpo de captura-antígeno, em que o anticorpo de captura compete com o anticorpo pela ligação a um primeiro epítopo no antígeno, (b) aplicar à fase sólida de um anticorpo traçador para formar um complexo anticorpo de captura-antígeno-anticorpo traçador, em que o anticorpo traçador se liga especificamente a um segundo epítopo em o antígeno, em que o epítopo do anticorpo traçador não se sobrepõe ao epítopo do anticorpo de captura no antígeno, e (c) determinar o antígeno livre do anticorpo ao determinar o anticorpo traçador no complexo anticorpo de captura-antígeno-anticorpo traçador.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20180205 | 2020-06-16 | ||
PCT/EP2021/065880 WO2021254926A1 (en) | 2020-06-16 | 2021-06-14 | Method for determining the free antigen of an antibody in a sample |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022025675A2 true BR112022025675A2 (pt) | 2023-03-07 |
Family
ID=71103268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022025675A BR112022025675A2 (pt) | 2020-06-16 | 2021-06-14 | Método para determinar antígeno livre |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230393125A1 (pt) |
EP (1) | EP4165409A1 (pt) |
JP (1) | JP2023530977A (pt) |
KR (1) | KR20230017308A (pt) |
CN (1) | CN115917320A (pt) |
AU (1) | AU2021294222A1 (pt) |
BR (1) | BR112022025675A2 (pt) |
CA (1) | CA3183441A1 (pt) |
IL (1) | IL298923A (pt) |
MX (1) | MX2022015899A (pt) |
WO (1) | WO2021254926A1 (pt) |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2095818B (en) | 1981-03-27 | 1985-10-02 | Exxon Research Engineering Co | Staged adsorption/resorption heat pump |
US5238808A (en) | 1984-10-31 | 1993-08-24 | Igen, Inc. | Luminescent metal chelate labels and means for detection |
ATE180057T1 (de) | 1988-11-03 | 1999-05-15 | Igen Int Inc | Elektrochemilumineszente testverfahren |
US5068088A (en) | 1988-11-03 | 1991-11-26 | Igen, Inc. | Method and apparatus for conducting electrochemiluminescent measurements |
IL100866A (en) | 1991-02-06 | 1995-10-31 | Igen Inc | Luminescence test method and device based on magnetic tiny particles, containing many magnets |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
AU2002216314A1 (en) | 2000-10-12 | 2002-04-22 | Scott A Henderson | Heterocyclic angiogenesis inhibitors |
JP4958387B2 (ja) | 2001-08-17 | 2012-06-20 | ジェネンテック, インコーポレイテッド | C5bの形成を妨害することなくc5及びc5aに結合する補体経路阻害剤 |
FR2842069B1 (fr) | 2002-07-12 | 2004-09-10 | Pellenc Sa | Effeuilleuse, plus specialement destinee a l'effeuillage selectif de la vigne |
US20050148975A1 (en) | 2003-12-31 | 2005-07-07 | Kimberly-Clark Worldwide, Inc. | Disposable garment having an elastic inner layer with a narrow width in the crotch region |
WO2007096586A1 (en) | 2006-02-20 | 2007-08-30 | Pepperl & Fuchs (De) | Fieldbus physical layer diagnostics data conversion device |
WO2008060790A2 (en) | 2006-10-13 | 2008-05-22 | Ochsner Clinic Foundation | Detection of ckd or cad using bmp-4 |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
PL2328616T3 (pl) | 2008-08-05 | 2015-10-30 | Novartis Ag | Kompozycje i sposoby dla przeciwciał celujących białko dopełniacza C5 |
AU2009313203B2 (en) | 2008-11-10 | 2015-08-27 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating complement-associated disorders |
JP5501439B2 (ja) | 2009-04-02 | 2014-05-21 | ロシュ グリクアート アクチェンゲゼルシャフト | 完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体 |
KR101456326B1 (ko) | 2009-04-07 | 2014-11-12 | 로슈 글리카트 아게 | 3가, 이중특이적 항체 |
RU2570633C2 (ru) | 2009-05-27 | 2015-12-10 | Ф.Хоффманн-Ля Рош Аг | Три- или тетраспецифические антитела |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
CA2876455A1 (en) | 2012-08-08 | 2014-02-13 | F.Hoffmann-La Roche Ag | Immunoassay-based determination of in-solution binding kinetics |
WO2015144783A1 (en) | 2014-03-28 | 2015-10-01 | Curiosity Diagnostics Sp. Z O.O. | Device for simultaneous and uniform thermal cycling of samples and uses thereof |
EP3529618B1 (en) | 2016-10-19 | 2020-12-02 | Alexion Pharmaceuticals, Inc. | A method of quantitating unbound c5 in a sample |
-
2021
- 2021-06-14 JP JP2022577318A patent/JP2023530977A/ja active Pending
- 2021-06-14 IL IL298923A patent/IL298923A/en unknown
- 2021-06-14 WO PCT/EP2021/065880 patent/WO2021254926A1/en unknown
- 2021-06-14 AU AU2021294222A patent/AU2021294222A1/en active Pending
- 2021-06-14 BR BR112022025675A patent/BR112022025675A2/pt unknown
- 2021-06-14 CA CA3183441A patent/CA3183441A1/en active Pending
- 2021-06-14 MX MX2022015899A patent/MX2022015899A/es unknown
- 2021-06-14 CN CN202180043437.1A patent/CN115917320A/zh active Pending
- 2021-06-14 EP EP21732874.9A patent/EP4165409A1/en active Pending
- 2021-06-14 KR KR1020227046185A patent/KR20230017308A/ko unknown
-
2022
- 2022-12-16 US US18/067,567 patent/US20230393125A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230017308A (ko) | 2023-02-03 |
WO2021254926A1 (en) | 2021-12-23 |
IL298923A (en) | 2023-02-01 |
JP2023530977A (ja) | 2023-07-20 |
EP4165409A1 (en) | 2023-04-19 |
MX2022015899A (es) | 2023-01-24 |
CN115917320A (zh) | 2023-04-04 |
US20230393125A1 (en) | 2023-12-07 |
AU2021294222A1 (en) | 2023-01-19 |
CA3183441A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Reyes et al. | Four monoclonal antibodies against capsular polysaccharides of Neisseria meningitidis serogroups A, C, Y and W135: its application in identity tests | |
BR112022013545A2 (pt) | Anticorpos anti-tigit e método de uso | |
ATE236398T1 (de) | Verbessertes verfahren zum nachweis von säure- resistenten bakterien der gattung helicobacter im stuhl | |
RU2016107435A (ru) | Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты | |
Palmieri et al. | Development of an analytical protocol for a fast, sensitive and specific protein recognition in paintings by enzyme-linked immunosorbent assay (ELISA) | |
EA201100527A1 (ru) | Биологические продукты | |
BR112022011669A2 (pt) | Anticorpos biespecíficos caninizados e parceiros de ligação biespecíficos para tratar dermatite atópica | |
BR112021026089A2 (pt) | Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos | |
JP2019015737A5 (pt) | ||
HRP20171623T1 (hr) | Poboljšana cjepivna dijagnostika | |
US20110195525A1 (en) | Method of use and Apparatus for an Enhanced Lateral Flow Rapid Test Device | |
JP2019015736A5 (pt) | ||
BR112022025675A2 (pt) | Método para determinar antígeno livre | |
RU2015107740A (ru) | Способ измерения, реагент для измерения и набор для измерения pivka-ii | |
BR112019007096A2 (pt) | método para a detecção de apolipoproteína e4 | |
JP7455947B2 (ja) | アデノウイルスの免疫測定方法及び免疫測定器具 | |
Riches-Duit et al. | Characterisation of diphtheria monoclonal antibodies as a first step towards the development of an in vitro vaccine potency immunoassay | |
BR112022002376A2 (pt) | Anticorpos que se ligam especificamente à troponina t cardíaca humana, anticorpos, moléculas de ácido nucleico, vetor, composição e método para determinar a troponina t cardíaca humana | |
BR112023016713A2 (pt) | Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo | |
KR102569269B1 (ko) | 피검 대상의 검출 방법 및 그것을 위한 면역 측정 기구 및 모노클로널 항체 | |
BR112022004570A2 (pt) | Terapia de combinação com anticorpos entpd2 e cd73 | |
Manouvriez | Use of anti-rat kappa light chain allotype monoclonal antibodies for the quantification of rat monoclonal antibodies in ascitic fluid or serum | |
BR112022024161A2 (pt) | Anticorpo multiespecífico, sequência de ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo multiespecífico e composição farmacêutica | |
KR880013013A (ko) | 액체 샘플내 다가 항원의 정량시약 및 면역화학적 정량방법 | |
González et al. | Monoclonal antibodies against the capsular polysaccharides A, C, Y, W, and X of Neisseria meningitidis: a platform for the quality control of meningococcal vaccines |